.
.
.
.

US scientists doubtful of one-shot regimen for Pfizer, Moderna COVID-19 vaccines: WSJ

Published: Updated:

U.S. scientists are skeptical of a one-shot regimen for Pfizer Inc and Moderna Inc COVID-19 vaccines, saying there isn't enough evidence that a single dose provides long-term protection, the Wall Street Journal reported.

"It is essential that these vaccines be used as authorized by FDA in order to prevent Covid-19 and related hospitalizations and death," Peter Marks, director of the FDA's Center for Biologics Evaluation and Research, told the Journal.

Visit our dedicated coronavirus site here for all the latest updates.

One dose of the Pfizer-BioNTech vaccine offers two-thirds protection against coronavirus, data seen by the U.K. government suggests.

Early findings from the U.K.’s vaccination program, due to be released within days, show that the first dose reduced the symptomatic infection risk among patients by 65% in younger adults and 64% in over-80s, a person familiar with the matter said in February.

The data, first reported by The Sun newspaper, showed that two doses of the Pfizer vaccine saw protection rise to between 79% and 84%, depending on age. The AstraZeneca vaccine offers similar protection, the newspaper said.

Read more:

Johnson & Johnson requests emergency authorization for one-shot coronavirus vaccine

Explainer: Coronavirus shots might be tweaked if variants get worse